India’s pharmaceutical ecosystem is undergoing a major regulatory shift. Recent actions by the Central Drugs Standard Control Organisation (CDSCO) have placed thousands of small and medium drug manufacturers under strict scrutiny. As the regulator moves aggressively to verify compliance with Schedule M Good Manufacturing Practices (GMP), many small pharma units fear closure because they lack the funds required for large-scale upgrades.
This sudden enforcement wave has created anxiety within the pharmaceutical MSME sector, which contributes significantly to India’s medicine supply—especially in rural and semi-urban markets.
Thousands of MSME Pharma Firms at Risk
Industry associations state that nearly 5,000 drug manufacturing plants may be forced to halt operations if they fail to upgrade their facilities in time. These units operate with limited margins, and the capital required for upgrading infrastructure, equipment, and documentation systems is often beyond reach.
A joint forum of MSME pharma bodies has warned that the industry may even initiate strikes if the government does not extend the compliance timeline. They argue that an abrupt shutdown of so many units could lead to serious medicine shortages, especially for essential therapies produced at regional levels.
For business owners looking to diversify or shift their model, many are exploring new opportunities like partnering with a monopoly medicine company in India, which allows them to reduce operational pressure and focus on marketing rather than manufacturing.
CDSCO Orders State-wide Inspections
The latest CDSCO order instructs state drug controllers to conduct full site inspections to verify whether companies meet the revised Schedule M norms. This includes checking:
-
Manufacturing area design
-
Quality control procedures
-
Documentation systems
-
Personnel hygiene and training
-
Recall mechanisms for defective products
Industry experts fear that the strict execution of these inspections may result in mass closure notices, leaving thousands unemployed and disrupting local economies.
Industry leaders like Rajesh Gupta (Laghu Udyog Bharati Pharma Committee) argue that rather than pushing MSMEs towards closure, the government should offer subsidies, training, and infrastructure support—especially because these units played an essential role during the COVID-19 crisis.
What Is Schedule M and Why Does It Matter?
Schedule M, part of the Drugs and Cosmetics Rules, 1945, outlines the Good Manufacturing Practices required for pharmaceutical manufacturers. It covers every aspect of production, from building maintenance to documentation and quality control.
In January 2022, India notified a revised version of Schedule M to align domestic manufacturing with international standards.
The compliance deadlines were:
-
Turnover above ₹250 crore – Deadline: July 1, 2023
-
MSME units below ₹250 crore – Deadline: January 1, 2024
Many smaller companies argue that this timeline is unrealistic for firms still recovering financially from the pandemic and rising raw material costs.
Some are considering outsourcing their production to a certified pharma contract manufacturing company, which offers a more cost-effective way to stay compliant without shutting down operations.
Possible Drug Shortages if MSMEs Shut Down
A large portion of India’s essential, generic, and low-cost medicines are produced by MSME pharma units. Sudden closures could create:
-
Shortage of antibiotics
-
Limited supply of chronic disease medicines
-
Disruption of hospital procurement cycles
-
Higher medicine prices for consumers
This is why industry bodies are urging regulators to consider a phased implementation rather than a rapid crackdown.
Extension Through Gap Analysis
The government has allowed firms to request an extension, provided they complete a Gap Analysis Report outlining:
-
Current GMP status
-
Infrastructure deficiencies
-
Required upgrades
-
A clear implementation timeline
However, many companies still feel burdened by the financial cost and hope for additional government incentives, tax reliefs, or compliance-based subsidies.
Conclusion
The tightening of quality checks marks an important step toward elevating India’s pharmaceutical reputation globally. However, without financial support and extended timelines, thousands of MSME pharma units may face closure—leading to job losses and medicine shortages.
To survive this transition, many small manufacturers are exploring sustainable business models such as partnering with a monopoly medicine company in India or outsourcing production to a reliable pharma contract manufacturing company to remain competitive without heavy manufacturing costs.